Sort
48,018 grants matching “immunotherapy”
Biomarker Investigations for Clinical Trials
$1,025,905Liang Cao · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Immunological Analysis of Brain Cancer
$1,025,686Masaki Terabe · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
PEDIATRIC AIDS CLINICAL TRIALS UNIT
$1,025,528New York University School Of Medicine · U01 · FY2001 · AI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses
$1,025,389Wayne A. Marasco · Dana-Farber Cancer Inst · R01 · FY2013 · AI
PATHWAYS TO TOLERANCE IN HUMAN ISLET TRANSPLANTATION
$1,025,208University Of Miami School Of Medicine · R01 · FY2002 · DK
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
$1,024,986Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI
Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma
$1,024,973Yen Tun Wang · Curebiotech, Inc. · R44 · FY2019 · CA
Dissecting innate immune control of intestinal and systemic Yersinia infection
$1,024,897Igor E Brodsky · University Of Pennsylvania · R01 · FY2025 · AI
Coordinating and Data Management Center for Acquired Resistance to Therapy Network
$1,024,775Alan David Hutson · Roswell Park Cancer Institute Corp · U24 · FY2023 · CA
Reprogramming the Tumor-Immune Interface in Oral Cancer
$1,024,729John B Sunwoo · Stanford University · R35 · FY2021 · DE
Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization and imaging
$1,024,684Robert A Salata · Case Western Reserve University · U54 · FY2020 · CA
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma
$1,024,390John H Sampson · Duke University · U01 · FY2016 · NS
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma
$1,023,920Frances L Johnson · Viewpoint Molecular Targeting, Inc. · R44 · FY2020 · CA
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
$1,023,875Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
Monoclonal Antibodies for Alzheimer's Immunotherapy
$1,023,870Andrew C Hiatt · Mapp Biopharmaceutical, Inc. · R44 · FY2010 · AG
Super-Resolution OMX Microscrope
$1,023,721Tomasz Zal · University Of Tx Md Anderson Can Ctr · S10 · FY2011 · RR
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
$1,023,709Matthew L Meyerson · Dana-Farber Cancer Inst · R35 · FY2022 · CA
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
$1,023,709Matthew L Meyerson · Dana-Farber Cancer Inst · R35 · FY2023 · CA
Immunotherapy of low grade lymphoid malignancies
$1,023,663Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL
Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies
$1,023,609Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Philadelphia Pediatric AIDS Clinical Trials Unit
$1,023,391Childrens Hospital Of Philadelphia · U01 · FY2004 · AI
STRATEGIES TO COUNTERACT RESISTANCE MECHANISMS IN CAR+ T-CELL-BASED IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER
$1,023,084The General Hospital Corporation · · FY2016 · Department of the Army
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeutics
$1,022,649Kartik Chandran · Albert Einstein College Of Medicine · R01 · FY2018 · AI
COMBINING ANDROGEN DEPRIVATION AND IMMUNOTHERAPY TO PREVENT PROGRESSION TO CASTRATION-RESISTANT PROSTATE CANCER
$1,022,588Health Research, Inc. · · FY2019 · Defense Health Agency
Molecular Pathogenesis of Neoplasia
$1,022,497Richard Youle · National Institute Of Neurological Disorders And Stroke · ZIA · FY2017 · NS